N-Gene Overview
- Year Founded
-
1997
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
2ndary - Private
- Financing Rounds
-
9
N-Gene General Information
Description
Developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical businesses to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy and slow skin aging.
Contact Information
Website
www.ngene.usCorporate Office
- 575 Madison Avenue
- 10th Floor
- New York, NY 10022
- United States
Corporate Office
- 575 Madison Avenue
- 10th Floor
- New York, NY 10022
- United States
N-Gene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
N-Gene Patents
N-Gene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023454616-A1 | Increasing telomere length and/or suppressing telomere shortening | Pending | 10-Jul-2023 | ||
| EP-4743072-A1 | Increasing telomere length and/or suppressing telomere shortening | Pending | 10-Jul-2023 | ||
| WO-2025014519-A1 | Increasing telomere length and/or suppressing telomere shortening | Inactive | 10-Jul-2023 | ||
| WO-2025014519-A9 | Increasing telomere length and/or suppressing telomere shortening | Inactive | 10-Jul-2023 | ||
| WO-2020044067-A1 | Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects | Inactive | 30-Aug-2018 | A61K31/4545 |
N-Gene Signals
N-Gene Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
N-Gene FAQs
-
When was N-Gene founded?
N-Gene was founded in 1997.
-
Where is N-Gene headquartered?
N-Gene is headquartered in New York, NY.
-
What is the size of N-Gene?
N-Gene has 8 total employees.
-
What industry is N-Gene in?
N-Gene’s primary industry is Drug Discovery.
-
Is N-Gene a private or public company?
N-Gene is a Private company.
-
What is N-Gene’s current revenue?
The current revenue for N-Gene is .
-
How much funding has N-Gene raised over time?
N-Gene has raised $40.1M.
-
Who are N-Gene’s investors?
Phylaxia and Allos Therapeutics have invested in N-Gene.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process